[Metacognitive deficit in schizophrenia: Characteristics and links].

Déficit métacognitif dans la schizophrénie : caractéristiques et liens.

Journal

L'Encephale
ISSN: 0013-7006
Titre abrégé: Encephale
Pays: France
ID NLM: 7505643

Informations de publication

Date de publication:
Aug 2022
Historique:
received: 29 01 2021
revised: 18 04 2021
accepted: 30 04 2021
pubmed: 21 9 2021
medline: 2 8 2022
entrez: 20 9 2021
Statut: ppublish

Résumé

Research indicates that many patients with schizophrenia experience deficits in metacognitive capacity defined as the ability to form complex representations of themselves and others. The aim of the current study was to assess metacognitive deficit in patients with schizophrenia. These variables were collected together with many other sociodemographic, clinical and therapeutic data. We conducted a descriptive and analytical cross-sectional study in the psychiatry department at the Hedi Chaker University Hospital in Sfax (Tunisia). Patients were in a non-acute phase, defined by the absence of any psychiatric symptoms during the last four weeks, also, no changes in medication during the previous month had been required. An informed written consent was obtained, following which patients completed questionnaires assessing sociodemographic and clinical data during structured interviews. Symptoms and severity of the illness were assessed using the Positive and Negative Symptoms Scale (PANSS). Insight was assessed using the Insight Scale (Q8). In addition, the Metacognition Assessment Scale-Abbreviated (MAS-A) was used to assess metacognitive capacities. The MAS-A contains four dimensions: self-reflectivity, awareness of the mind of others, decentration, and mastery. Higher scores reflect an ability to effectively respond to psychological challenges on the basis of psychological knowledge. We recruited 74 adults with schizophrenia disorder. The diagnosis was with DSM5. Their average age was 45 years (SD=9.84 years) with a sex ratio (M/F) of 1.552. Nineteen patients (25.5%) were married, and low educational level was present in 43% of cases. Forty patients (54%) were unemployed. Metacognitive deficit was detected in all the patients. They had low levels in all four dimensions of metacognition. The most affected dimension in our series was "Mastery". All patients had an overall insight score less than six (the average score was 2.73) with poor awareness in 62% of patients. The main factors correlated with metacognitive deficit were: occupational inactivity (P-0.015), Primary education level (P=0.045), tobacco consumption (P=0.002), low insight (P-0.001), negative symptomatology (P<10-3) and the use of first generation of antipsychotics (P=0.003). The multivariate analysis showed that three factors (occupational inactivity, low insight and the presence of negative symptomatology) were predictors of metacognitive deficits. Based on our results, occupational inactivity, negative symptomatology and low insight are predictors of metacognitive deficit in schizophrenia. Specific therapeutics should be proposed to act on these factors. A metacognitive training program, tailored to this vulnerable population, is a priority to improve their quality of life.

Identifiants

pubmed: 34538624
pii: S0013-7006(21)00150-0
doi: 10.1016/j.encep.2021.04.004
pii:
doi:

Types de publication

Journal Article

Langues

fre

Sous-ensembles de citation

IM

Pagination

415-421

Informations de copyright

Copyright © 2021 L'Encéphale, Paris. Published by Elsevier Masson SAS. All rights reserved.

Auteurs

M Daoud (M)

Service de psychiatrie « C », CHU d'Hédi-Chaker, Sfax, Tunisie; Faculté de médecine de Sfax, université de Sfax, Sfax, Tunisie. Electronic address: daoud_maroua@hotmail.com.

J Ben Thabet (J)

Service de psychiatrie « C », CHU d'Hédi-Chaker, Sfax, Tunisie; Faculté de médecine de Sfax, université de Sfax, Sfax, Tunisie.

M Maalej Bouali (M)

Service de psychiatrie « C », CHU d'Hédi-Chaker, Sfax, Tunisie; Faculté de médecine de Sfax, université de Sfax, Sfax, Tunisie.

S Omri (S)

Service de psychiatrie « C », CHU d'Hédi-Chaker, Sfax, Tunisie; Faculté de médecine de Sfax, université de Sfax, Sfax, Tunisie.

I Gassara (I)

Service de psychiatrie « C », CHU d'Hédi-Chaker, Sfax, Tunisie; Faculté de médecine de Sfax, université de Sfax, Sfax, Tunisie.

R Feki (R)

Service de psychiatrie « C », CHU d'Hédi-Chaker, Sfax, Tunisie; Faculté de médecine de Sfax, université de Sfax, Sfax, Tunisie.

N Smaoui (N)

Service de psychiatrie « C », CHU d'Hédi-Chaker, Sfax, Tunisie; Faculté de médecine de Sfax, université de Sfax, Sfax, Tunisie.

L Zouari (L)

Service de psychiatrie « C », CHU d'Hédi-Chaker, Sfax, Tunisie; Faculté de médecine de Sfax, université de Sfax, Sfax, Tunisie.

N Charfi (N)

Service de psychiatrie « C », CHU d'Hédi-Chaker, Sfax, Tunisie; Faculté de médecine de Sfax, université de Sfax, Sfax, Tunisie.

M Maalej (M)

Service de psychiatrie « C », CHU d'Hédi-Chaker, Sfax, Tunisie; Faculté de médecine de Sfax, université de Sfax, Sfax, Tunisie.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH